Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.60 |
| ▸ | CNR1 | P21554 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817624 | 1.00 | CNR2 (0.60) | CNR2CNR1KDM4EALDH1A1HPGD | |
| SCHEMBL16581429 | 0.90 | CNR2 (0.60) | CNR2CNR1KDM4EALDH1A1HPGD | |
| SCHEMBL16581428 | 0.90 | CNR2 (0.60) | CNR2CNR1KDM4EALDH1A1HPGD | |
| SCHEMBL2817464 | 0.90 | CNR2 (0.61) | CNR2CNR1ALDH1A1 | |
| SCHEMBL2817463 | 0.90 | CNR2 (0.61) | CNR2CNR1ALDH1A1 | |
| SCHEMBL2814239 | 0.90 | CNR2 (0.64) | CNR2CNR1ALDH1A1 | |
| SCHEMBL2814242 | 0.90 | CNR2 (0.64) | CNR2CNR1ALDH1A1 | |
| SCHEMBL13990074 | 0.86 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL2813573 | 0.85 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL2813576 | 0.85 | CNR2 (0.65) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885KDM4E 1901/4885 |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885KDM4E 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.